T
Theodore F. Tsai
Researcher at Novartis
Publications - 33
Citations - 1749
Theodore F. Tsai is an academic researcher from Novartis. The author has contributed to research in topics: Influenza vaccine & Vaccination. The author has an hindex of 19, co-authored 33 publications receiving 1547 citations.
Papers
More filters
Journal ArticleDOI
Estimated global incidence of Japanese encephalitis: a systematic review
Grant L. Campbell,Susan L. Hills,Marc Fischer,Julie Jacobson,Charles H. Hoke,Joachim Hombach,Anthony A. Marfin,Tom Solomon,Theodore F. Tsai,Vivien Tsu,Amy Sarah Ginsburg +10 more
TL;DR: The estimate of the global incidence of JE remains substantial despite improvements in vaccination coverage, and more and better incidence studies in selected countries, particularly China and India, are needed to further refine these estimates.
Journal ArticleDOI
MF59 adjuvant: the best insurance against influenza strain diversity.
TL;DR: The ability of MF59 to increase the breadth of immune response against influenza vaccines is mainly due to the spreading of the repertoire of the B-cell epitopes recognized on the hemagglutinin and neuraminidase of the influenza virus.
Journal ArticleDOI
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy.
Theodore F. Tsai,Antonio Crucitti,Pantaleo Nacci,Uwe Nicolay,Giovanni Della Cioppa,Ferguson John F,Ralf Clemens +6 more
TL;DR: No case of narcolepsy and no evidence of an increased risk of sleep-related AEs were discovered in recipients of MF 59-adjuvanted A(H1N1) pandemic and other MF59-ad JuJuvanted influenza vaccine.
Patent
Vaccines including antigen from four strains of influenza virus
TL;DR: In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains as mentioned in this paper, and the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines.
Journal ArticleDOI
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
TL;DR: Experience thus far indicates a favorable balance of benefit to risk for MF59, which may reflect the adjuvant's mechanism of action in which the squalene oil emulsion increases antibody responses to co-administered antigen without acting more generally as an immunopotentiator.